Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis set for EU launch of Eucreas

Novartis set for EU launch of Eucreas

26th February 2008

Novartis has announced that it is set to launch Eucreas [Galvus (vildagliptin) and metformin] in the EU as a novel treatment for type two diabetes.

The company reports that patients whose condition is uncontrolled on metformin are four times as likely to achieve control of their blood sugar on Eucreas compared to those receiving a placebo.

It adds that Eucreas is the first single-tablet combination of metformin and a DPP-4 inhibitor to be approved for use in the EU, while use of the drug results in a low incidence of hypoglycemia and no overall weight gain.

The EU approved the drug following changes to labelling with the company recommending the initiation of liver monitoring after the start of treatment, to be conducted every three months during the first year and periodically after this point.

James Shannon, chief medical officer at Novartis Pharma, said: “The complementary actions of Galvus and metformin, which are the medicines combined in Eucreas, help to bring blood sugar levels under control without the side effects commonly associated with many widely-used type two diabetes medicines.”

He added that the approval of the drug marks significant progress in the management of the condition.

In November 2007, Novartis reported new clinical data that further confirmed the efficacy of Galvus as a treatment of type two diabetes.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.